7702   Agranulocytosis, acquired: Requiring bone marrow transplant; or infections recurring, on average, at least once every six weeks per 12-month period 100
7702   Agranulocytosis, acquired: Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or continuous immunosuppressive therapy such as cyclosporine to maintain absolute neutrophil count (ANC) greater than 500/microliter (µl) but less than 1000/µl; or infections recurring, on average, at least once every three months per 12-month period 60
7702   Agranulocytosis, acquired: Requiring intermittent myeloid growth factors to maintain ANC greater than 1000/µl; or infections recurring, on average, at least once per 12-month period but less than once every three months per 12-month period 30
7702   Agranulocytosis, acquired: Requiring continuous medication (e.g., antibiotics) for control; or requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl 10
7703   Leukemia (except for chronic myelogenous leukemia): When there is active disease or during a treatment phase 100
7703   Leukemia (except for chronic myelogenous leukemia): Otherwise rate residuals under the appropriate diagnostic code(s) Chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis (MBL), asymptomatic, Rai Stage 0 0
7704   Polycythemia vera: Requiring peripheral blood or bone marrow stem-cell transplant or chemotherapy (including myelosuppressants) for the purpose of ameliorating the symptom burden 100
7704   Polycythemia vera: Requiring phlebotomy 6 or more times per 12-month period or molecularly targeted therapy for the purpose of controlling RBC count 60
7704   Polycythemia vera: Requiring phlebotomy 4-5 times per 12-month period, or if requiring continuous biologic therapy or myelosuppressive agents, to include interferon, to maintain platelets <200,000 or white blood cells (WBC) <12,000
7704   Polycythemia vera: 30
7704   Polycythemia vera: Requiring phlebotomy 3 or fewer times per 12-month period or if requiring biologic therapy or interferon on an intermittent basis as needed to maintain all blood values at reference range levels 10
7704   Polycythemia vera: Note (1): Rate complications such as hypertension, gout, stroke, or thrombotic disease separately Note (2): If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703
7705   Immune thrombocytopenia: Requiring chemotherapy for chronic refractory thrombocytopenia; or a platelet count 30,000 or below despite treatment 100
7705   Immune thrombocytopenia: Requiring immunosuppressive therapy; or for a platelet count higher than 30,000 but not higher than 50,000, with history of hospitalization because of severe bleeding requiring intravenous immune globulin, high-dose parenteral corticosteroids, and platelet transfusions 70
7705   Immune thrombocytopenia: Platelet count higher than 30,000 but not higher than 50,000, with either immune thrombocytopenia or mild mucous membrane bleeding which requires oral corticosteroid therapy or intravenous immune globulin 30
7705   Immune thrombocytopenia: Platelet count higher than 30,000 but not higher than 50,000, not requiring treatment 10
7705   Immune thrombocytopenia: Platelet count above 50,000 and asymptomatic; or for immune thrombocytopenia in remission 0
7706   Splenectomy 20
7709   Hodgkin's lymphoma: With active disease or during a treatment phase 100
7712   Multiple myeloma: Symptomatic multiple myeloma 100
7712   Multiple myeloma: Asymptomatic, smoldering, or monoclonal gammopathy of undetermined significance (MGUS) 0
7714   Sickle cell anemia: With at least 4 or more painful episodes per 12-month period, occurring in skin, joints, bones, or any major organs, caused by hemolysis and sickling of red blood cells, with anemia, thrombosis, and infarction, with residual symptoms precluding even light manual labor 100
7714   Sickle cell anemia: With 3 painful episodes per 12-month period or with symptoms precluding other than light manual labor 60
7714   Sickle cell anemia: With 1 or 2 painful episodes per 12-month period 30
7714   Sickle cell anemia: Asymptomatic, established case in remission, but with identifiable organ impairment 10
7715   Non-Hodgkin's lymphoma: When there is active disease, during treatment phase, or with indolent and non-contiguous phase of low grade NHL 100
7716   Aplastic anemia: Requiring peripheral blood or bone marrow stem cell transplant; or requiring transfusion of platelets or red cells, on average, at least once every six weeks per 12-month period; or infections recurring, on average, at least once every six weeks per 12-month period 100
7716   Aplastic anemia: Requiring transfusion of platelets or red cells, on average, at least once every three months per 12-month period; or infections recurring, on average, at least once every three months per 12-month period; or using continuous therapy with immunosuppressive agent or newer platelet stimulating factors 60
7716   Aplastic anemia: Requiring transfusion of platelets or red cells, on average, at least once per 12-month period; or infections recurring, on average, at least once per 12-month period 30
7717   AL amyloidosis (primary amyloidosis) 100
7718   Essential thrombocythemia and primary myelofibrosis: Requiring either continuous myelosuppressive therapy or, for six months following hospital admission, peripheral blood or bone marrow stem cell transplant, or chemotherapy, or interferon treatment 100
7718   Essential thrombocythemia and primary myelofibrosis: Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment to maintain platelet count <500 × 10 /L 70
7718   Essential thrombocythemia and primary myelofibrosis: Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment to maintain platelet count of 200,000-400,000, or white blood cell (WBC) count of 4,000-10,000
7718   Essential thrombocythemia and primary myelofibrosis: 30
7718   Essential thrombocythemia and primary myelofibrosis: Asymptomatic 0
7718   Essential thrombocythemia and primary myelofibrosis: Note (1): If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703
7719   Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia): Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment 100
7719   Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia): Requiring intermittent myelosuppressive therapy, or molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission 60
7719   Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia): In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors 30
7719   Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia): Note (1): If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703
7720   Iron deficiency anemia: Requiring intravenous iron infusions 4 or more times per 12-month period 30
7720   Iron deficiency anemia: Requiring intravenous iron infusions at least 1 time but less than 4 times per 12-month period, or requiring continuous treatment with oral supplementation 10
7720   Iron deficiency anemia: Asymptomatic or requiring treatment only by dietary modification 0
7721   Folic acid deficiency: Requiring continuous treatment with high-dose oral supplementation 10
7721   Folic acid deficiency: Asymptomatic or requiring treatment only by dietary modification 0
7722   Pernicious anemia and Vitamin B12 deficiency anemia: For initial diagnosis requiring transfusion due to severe anemia, or if there are signs or symptoms related to central nervous system impairment, such as encephalopathy, myelopathy, or severe peripheral neuropathy, requiring parenteral B12 therapy 100
7722   Pernicious anemia and Vitamin B12 deficiency anemia: Requiring continuous treatment with Vitamin B12 injections, Vitamin B12 sublingual or high-dose oral tablets, or Vitamin B12 nasal spray or gel 10
7723   Acquired hemolytic anemia: Requiring a bone marrow transplant or continuous intravenous or immunosuppressive therapy (e.g., prednisone, Cytoxan, azathioprine, or rituximab) 100
7723   Acquired hemolytic anemia: 9
7723   Acquired hemolytic anemia: Requiring immunosuppressive medication 4 or more times per 12-month period 60
7723   Acquired hemolytic anemia: Requiring at least 2 but less than 4 courses of immunosuppressive therapy per 12-month period 30
7723   Acquired hemolytic anemia: Requiring one course of immunosuppressive therapy per 12-month period 10
7723   Acquired hemolytic anemia: Asymptomatic 0
7723   Acquired hemolytic anemia: Note (1): A 100 percent evaluation for bone marrow transplant shall be assigned as of the date of hospital admission and shall continue for six months after hospital discharge with a mandatory VA examination six months following hospital discharge. Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter Note (2): Separately evaluate splenectomy under diagnostic code 7706 and combine with an evaluation under diagnostic code 7723
7724   Solitary plasmacytoma: Solitary plasmacytoma, when there is active disease or during a treatment phase 100
7725   Myelodysplastic syndromes: Requiring peripheral blood or bone marrow stem cell transplant; or requiring chemotherapy 100
7725   Myelodysplastic syndromes: Requiring 4 or more blood or platelet transfusions per 12-month period; or infections requiring hospitalization 3 or more times per 12-month period 60
7725   Myelodysplastic syndromes: Requiring at least 1 but no more than 3 blood or platelet transfusions per 12-month period; infections requiring hospitalization at least 1 but no more than 2 times per 12- month period; or requiring biologic therapy on an ongoing basis or erythropoiesis stimulating agent (ESA) for 12 weeks or less per 12-month period 30
7725   Myelodysplastic syndromes: Note (1): If the condition progresses to leukemia, evaluate as leukemia under diagnostic code 7703
